{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:22:31Z","timestamp":1790360551783,"version":"4.1.0"},"reference-count":104,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T00:00:00Z","timestamp":1264636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Nurse Practitioners"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:p> <jats:bold>Purpose:<\/jats:bold> To highlight the characteristics of progestin\u2010only contraceptives (POCs) currently available in the United States, and to explore the potential of these agents as first\u2010line contraceptive options for women seeking health promotion by prevention of an unwanted pregnancy. The progestin\u2010only pills (Micronor and Ovrette), depot medroxyprogesterone acetate (DMPA) injections (Depo\u2010Provera and depo\u2010subQ provera 104), levonorgestrel intrauterine system (IUS) (Mirena), and etonogestrel implant (Implanon) will be reviewed. The use of levonorgestrel (Plan B) as an emergency contraceptive will also be considered briefly.<\/jats:p><jats:p> <jats:bold>Data sources:<\/jats:bold> Worldwide medical literature and the prescribing information for the specified products.<\/jats:p><jats:p> <jats:bold>Conclusions:<\/jats:bold> A number of POCs are currently available for routine birth control in the United States, ranging from the daily progestin\u2010only pill to nondaily contraceptive options such as injectable DMPA, the levonorgestrel\u2010releasing IUS, and the etonogestrel\u2010releasing contraceptive implant. Each of these methods has specific advantages, but also specific drawbacks that can result in discontinuation of treatment if users are not given adequate information about what to expect in terms of side effects. It is critical that clinicians provide adequate and accurate information along with detailed counseling to women who are considering using POCs, as well as providing periodic reinforcement of the information at regular clinic visits for those already using POCs.<\/jats:p><jats:p> <jats:bold>Implications for practice:<\/jats:bold> Given that a large number of pregnancies are unplanned and create a significant impact on social, economic, and health outcomes, it is important for the clinician to have a vast knowledge of contraceptive options. POCs offer significant choices in contraception. By proactively addressing common concerns (such as potential effects on weight, mood, menstrual bleeding patterns, and bone mineral density), clinicians may improve the likelihood of adherence and continuation with POCs for routine birth control.<\/jats:p>","DOI":"10.1111\/j.1745-7599.2009.00473.x","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T16:35:14Z","timestamp":1264696514000},"page":"81-91","source":"Crossref","is-referenced-by-count":15,"title":["Considerations for the use of progestin\u2010only contraceptives"],"prefix":"10.1111","volume":"22","author":[{"given":"Sarah","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee P.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,28]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"169","article-title":"Long\u2010acting progestogens. Best Practice & Research.","volume":"16","author":"Affandi B.","year":"2002","journal-title":"Clinical Obstetrics & Gynaecology"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(95)90279-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200606000-00055"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(92)90122-A"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.06.008"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2004.tb00369.x"},{"key":"e_1_2_7_8_1","first-page":"1839","article-title":"Using progestins in clinical practice","volume":"62","author":"Apgar B. S.","year":"2000","journal-title":"American Family Physician"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.03.008"},{"key":"e_1_2_7_10_1","unstructured":"Association of Reproductive Health Professionals. (n.d.).Obstacles to using extended contraceptive regimens. Retrieved November 12 2007 fromhttp:\/\/www.arhp.org\/healthcareproviders\/cme\/onlinecme\/ReduceMensesCP\/obstacles.cfm"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000178754.88912.b9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei358"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.1.118"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118902101195992"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00289-X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00181-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmb025"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1542\/peds.94.5.687","article-title":"A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo\u2010Provera), or the combined oral contraceptive pill as contraception","volume":"94","author":"Cromer B. A.","year":"1994","journal-title":"Pediatrics"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei290"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.4.976"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6923.247"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.122420"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.12.010"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00130-X"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(99)00043-8"},{"key":"e_1_2_7_26_1","unstructured":"Depo\u2010Provera [prescribing information]. (2006). New York: Pfizer."},{"key":"e_1_2_7_27_1","unstructured":"depo\u2010subQ provera 104 [prescribing information]. (2005). New York: Pfizer."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00144-X"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1783\/1471189053629356"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(91)90033-C"},{"key":"e_1_2_7_31_1","unstructured":"FDA Medical Officer Review. (2003). Retrieved February 7 2008 fromhttp:\/\/www.fda.gov\/OHRMS\/DOCKETS\/AC\/03\/briefing\/4015B1_12_FDA\u2010Tab%205\u20101\u2010Medical%20Officer%20Review.doc"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2004.tb00444.x"},{"key":"e_1_2_7_33_1","first-page":"CD003987","article-title":"Combination contraceptives: Effects on weight","volume":"2","author":"Gallo M. F.","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00284-0"},{"key":"e_1_2_7_35_1","first-page":"90","article-title":"Progestogen\u2010only contraception: A review","volume":"249","author":"Gupta S.","year":"2005","journal-title":"Practitioner"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/1054-139X(95)00322-J"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00302-X"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01849447"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(99)00104-3"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2003.09.002"},{"key":"e_1_2_7_41_1","unstructured":"Implanon [prescribing information]. (2006). Roseland NJ: Organon USA."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.01.011"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.06.011"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00283-9"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.1.216"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(94)05017-9"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8545(05)70171-6"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00182-7"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-200103000-00011"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.03.010"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.14.1766"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","unstructured":"Kjos S. L. Peters R. K. Xiang A. Thomas D. Schaefer U. &Buchanan T. A.(1998).Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus.Journal of the American Medical Association 280 533\u2013538.","DOI":"10.1001\/jama.280.6.533"},{"key":"e_1_2_7_53_1","first-page":"1375","article-title":"Use of oral contraceptives and breast cancer risk: The Norwegian\u2010Swedish Women's Lifestyle and Health Cohort Study","volume":"11","author":"Kumle M.","year":"2002","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.12.002"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10149"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.249.21.2909"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006133.pub2"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.11.004"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(95)00011-X"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.11.3057"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-3188(97)70039-1"},{"issue":"6","key":"e_1_2_7_62_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0010-7824(94)90113-9","article-title":"Progestin\u2010only oral contraception: A comprehensive review","volume":"50","author":"McCann M. F.","year":"1994","journal-title":"Contraception"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmg004"},{"key":"e_1_2_7_64_1","unstructured":"Mirena [prescribing information]. (2007). Montville NJ: Berlex Laboratories."},{"issue":"5","key":"e_1_2_7_65_1","first-page":"381","article-title":"Pharmacokinetics of depot medroxyprogesterone acetate contraception","volume":"41","author":"Mishell D. R.","year":"1996","journal-title":"Journal of Reproductive Medicine"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4755-4-11"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(95)00189-H"},{"key":"e_1_2_7_68_1","first-page":"1","article-title":"Use of contraception and use of family planning services in the United States: 1982\u20132002","volume":"350","author":"Mosher W. D.","year":"2004","journal-title":"Advance Data"},{"key":"#cr-split#-e_1_2_7_69_1.1","unstructured":"Myths About Oral Contraceptives. (2003).The contraception report 13"},{"key":"#cr-split#-e_1_2_7_69_1.2","unstructured":"(4) 14-15. Retrieved February 12 2008 fromhttp:\/\/www.contraceptiononline.org\/contrareport\/pdfs\/13_04.pdf"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00582.x"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00140-6"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/73.1.19"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200005000-00021"},{"key":"e_1_2_7_74_1","unstructured":"Plan B [prescribing information]. (2004). Pomona NY: Barr Pharmaceuticals."},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118902101196784"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-139X(98)00151-7"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(95)00074-K"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.07.1315"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/12.9.1851"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.2.139"},{"key":"e_1_2_7_81_1","unstructured":"Shelton J.(2005).FDA approval of SC Depo\u2010Provera. CCP: Pearl of the Week. Retrieved February 12 2008 fromhttp:\/\/www.jhuccp.org\/pearls\/pearl.php?id=301"},{"key":"e_1_2_7_82_1","first-page":"16","article-title":"Compliance and contraception: Sharing responsibility for improving outcomes","author":"Shulman L. P.","year":"1997","journal-title":"The Female Patient"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.01.064"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.2217\/17455057.2.2.191"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.12.3371"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(90)90046-X"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2003.12.015"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-3188(99)00039-X"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11159-0"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.013"},{"key":"e_1_2_7_91_1","first-page":"747","volume-title":"Contraceptive technology","author":"Trussell J.","year":"2007"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008945721786"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(03)00136-7"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.12.009"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(98)00024-9"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(95)00100-O"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490208"},{"key":"e_1_2_7_98_1","first-page":"191","article-title":"Depot\u2010medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.","volume":"49","author":"World Health Organization","year":"1991","journal-title":"International Journal of Cancer"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(92)90052-U"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(98)00041-9"},{"key":"e_1_2_7_101_1","unstructured":"World Health Organization. (1999).IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 72. Hormonal Contraception and Post\u2010menopausal Hormonal Therapy. International Agency for Research on Cancer Lyon France."},{"key":"e_1_2_7_102_1","unstructured":"World Health Organization. (2004).Medical eligibility criteria for contraceptive use(3rd ed.). Retrieved January 10 2008 fromhttp:\/\/www.who.int\/reproductivehealth\/publications\/mec\/"},{"key":"e_1_2_7_103_1","unstructured":"World Health Organization. (2005).WHO statement on hormonal contraception and bone health. Retrieved January 10 2008 fromhttp:\/\/www.who.int\/reproductive\u2010health\/family_planning\/bone_health.html"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.03.06.dc05-1940"}],"container-title":["Journal of the American Academy of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1745-7599.2009.00473.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1745-7599.2009.00473.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:29:34Z","timestamp":1694622574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1745-7599.2009.00473.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,28]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1745-7599.2009.00473.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1745-7599.2009.00473.x","archive":["Portico"],"relation":{},"ISSN":["1041-2972","1745-7599"],"issn-type":[{"value":"1041-2972","type":"print"},{"value":"1745-7599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,28]]}}}